Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study

Abstract

Background: Chronic inflammatory diseases (CIDs; ankylosing spondylitis [AS], psoriatic arthritis [PsA], psoriasis [PsO], or rheumatoid arthritis [RA]) and inflammatory bowel disease (IBD; Crohn's disease and ulcerative colitis) are associated with substantial economic burden. The relative increased costs among patients with CIDs and concomitant IBD compared to those without IBD is an important consideration when deciding on the clinical management of patient symptoms. Given the increasing use of novel agents for the treatment of CIDs, including those that may increase the risk of IBD in patients with CIDs, the objective of the study was to describe the incidence of IBD and to quantify healthcare resource utilization (HRU) and costs associated with IBD among patients with CIDs. Methods: The IBM MarketScan® Research Databases (1/2010-7/2017) were used to identify adult patients with ≥2 claims with a diagnosis of either AS/PsA/PsO/RA (index date was a random claim for AS/PsA/PsO/RA). The one-year incidence rate of IBD was calculated following the index date. HRU and healthcare costs were compared between patients developing and not developing IBD in the year following the index date, adjusting for baseline characteristics. Results: A total of 537,450 patients with CIDs (mean age = 54.0 years; 63.1% female) were included in the study. The 1-year incidence rate of IBD was 0.52% (range = 0.39% in patients with PsO but without PsA to 1.73% in patients with AS). Patients who developed IBD (N = 2778) had significantly higher rates of inpatient, outpatient, and emergency room visits (incidence rate ratios [IRR] = 2.91, 1.35, 1.81; all P < 0.0001), compared to patients without IBD

The Impact of Inflammatory Bowel Disease on Mortality and Other Outcomes of Hospitalized Patients With Diabetic Ketoacidosis: An Observational Study of the United States National Inpatient Sample

“…Finally, our study showed that patients who were admitted with DKA and IBD had a longer length of hospital stay and higher COC. These values of higher healthcare resources utilization correlate favorably with previous evidence from Hudesman et al [ 34 ], and are explained by the increased requirement of therapeutic measures and specialty services for patients with IBD, as a result of the well-known relation between IBD and other comorbid pathologies which make the management of the DKA more complicated, mandating an increase in both lengths of hospital and COC.…”

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

“…15 International studies reported colectomies in 7%-10% of patients with UC, with decreasing colectomy rates over recent years. [16][17][18] Active UC is associated with reduced health-related quality of life (HRQoL) and productivity, [19][20][21][22][23][24] frequent visits to accident and emergency departments (A&E), hospital stays and healthcare costs, [24][25][26] with greater costs with increasing frequency of relapse. 27 Although colectomy may be life-saving, it was recommended not to be considered a cure for UC.…”

Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China

“…IBD has become a global disease with an accelerating incidence in newly industrialized countries 2 . Characterized by a relapsing and remitting course, patients with IBD need close monitoring and therapy adjustment for an optimal disease management, which requires high health‐care resource utilization and costs 3 . However, the impact of such unprecedented situation of COVID‐19 outbreak on health care of patients with IBD in real‐world setting has seldom been investigated.…”